Replies to post #23455 on NorthWest Biotherapeutics Inc (NWBO)

[mapman1010]

Thank you gnawkz. Very reassuring.

[Rkmatters]

Really great discussion. :)

[flipper44]

Gnawks, thanks for your post (#23455). Extremely enlightening, as is Pyrrr's post (#23444). I reprinted both messages below.

I use to work for a department in a large university responsible for licensing patents and technology and managing external relationships.

The University is bounded by restrictions built into contracts that prevent it from licensing technology / patents / or other research to multiple parties, especially parties with competing interests. This was pretty standard language in most of the contracts that were signed, unless there were specific other clauses.

The University is not looking to invest in companies or be in any specific industry. Rather the goal of the department and university was to establish long streams of royalty that would ultimately reward professors for all their years of research and work.

In addition, the university takes a substantial cut of the royalty payments and is able to leverage these relationships with large corporations to build more scholarship funding and establish themselves as a key feeder school for these companies.

My university saw these patents and technology as a strategic advantage, not just for the revenue stream, honors and recognition, but also another way of creating future companies and jobs for the next graduating class.

Pyrr has laid out all of the qualitative benefits. -- Gnawks

The exclusive manufacturing rights to DCVax as well as all patents are in the possession and at the sole discretion of NWBO. If anyone is under constraint it is UCLA. They can no longer mention in any study "partially matured DCs loaded with whole tumor lysate," but have to say "DCVax" in all of their testing and trials. They handed over the rights to this vacc to NWBO in return for many obvious privileges. Liau is the PI for the Ph III trial and UCLA the primary institution. Going forward UCLA will be the hub of corporate funded (NWBO) scientific exploration using DCVax. I'm sure there are many arrangements set up for UCLA to manage and have a hand in all of the various trials that will be enacted once DCVax-L is approved. In other words, a massive influx of grant money, as well as full recognition for developing the groundbreaking vaccine. That's the extent of it in public records, and that's plenty for them. So if [anyone is] suggesting some cut of the profits going to UCLA, thats just not true, as it would require disclosure (as we've seen in some of MDA's deals). -- Pyrr